Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/80329
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Trott, D. | - |
dc.date.issued | 2013 | - |
dc.identifier.citation | Current Pharmaceutical Design, 2013; 19(2):239-249 | - |
dc.identifier.issn | 1381-6128 | - |
dc.identifier.issn | 1873-4286 | - |
dc.identifier.uri | http://hdl.handle.net/2440/80329 | - |
dc.description.abstract | Although β-lactams remain a cornerstone of veterinary therapeutics, only a restricted number are actually approved for use in food-producing livestock in comparison to companion animals and wildlife. Nevertheless, both registered and off-label use of third and fourth-generation cephalosporins in livestock may have influenced the emergence of plasmid-encoded AmpC β-lactamases (pAmpC) (mainly CMY-2) and CTX-M extended-spectrum β-lactamases (ESBLs) in both Gram-negative pathogens and commensals isolated from animals. This presents a public health concern due to the potential risk of transfer of β-lactam-resistant pathogens from livestock to humans through food. The recent detection of pAmpC and ESBLs in multidrug-resistant Enterobacteriaceae isolated from dogs has also confirmed the public health importance of β-lactam resistance in companion animals, though in this case, human-to-animal transmission may be equally as relevant as animal-to-human transmission. Identification of pAmpC and ESBLs in Enterobacteriaceae isolated from wildlife and aquaculture species may be evidence of environmental selection pressure arising from both human and veterinary use of β- lactams. Such selection pressure in animals could be reduced by the availability of reliable alternative control measures such as vaccines, bacteriophage treatments and/or competitive exclusion models for endemic production animal diseases such as colibacillosis. The global emergence and pandemic spread of extraintestinal pathogenic E. coli O25-ST131 strains expressing CTX-M-15 ESBL in humans and its recent detection in livestock, companion animals and wildlife is a major cause for concern and goes against the paradigm that Gramnegative pathogens do not necessarily have to lose virulence in compensation for acquiring resistance. | - |
dc.description.statementofresponsibility | Darren Trott | - |
dc.language.iso | en | - |
dc.publisher | Bentham Science Publ Ltd | - |
dc.rights | Copyright status unknown | - |
dc.source.uri | http://dx.doi.org/10.2174/138161213804070339 | - |
dc.subject | Escherichia coli | - |
dc.subject | Extended-spectrum | - |
dc.subject | ST131 | - |
dc.subject | antimicrobial resistance | - |
dc.subject | companion animals | - |
dc.subject | livestock | - |
dc.subject | β-lactamases | - |
dc.title | β-lactam resistance in gram-negative pathogens isolated from animals | - |
dc.title.alternative | beta-lactam resistance in gram-negative pathogens isolated from animals | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.2174/138161213804070339 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Trott, D. [0000-0002-8297-5770] | - |
Appears in Collections: | Animal and Veterinary Sciences publications Aurora harvest 4 |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.